首页> 美国卫生研究院文献>British Journal of Clinical Pharmacology >The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction.
【2h】

The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction.

机译:6β-羟基皮质醇作为人肝细胞色素P450IIIA诱导标记的尿排泄增加。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

1. Urinary excretion of 6 beta-hydroxycortisol, hepatic microsomal cortisol 6 beta-hydroxylase and the specific content of several forms of cytochrome P450 were measured in 8 to 14 patients before and after treatment with rifampicin (600 mg orally per day for 4 days). 2. Rifampicin treatment produced an average five fold increase in daily excretion of urinary 6 beta-hydroxycortisol. 3. Cortisol 6 beta-hydroxylase activity increased from 15 +/- 6 pmol min-1 mg-1 in organ donors (considered as 'control subjects') to 87 +/- 31 pmol min-1 mg-1 in rifampicin treated patients. 4. Among three forms of human P450 (P450IA, IIC and IIIA), (1), (2), measured by Western blots, only P450IIIA was significantly induced by the antibiotic. 5. Only antibodies against P450IIIA selectively inhibited cortisol 6 beta-hydroxylase in human liver microsomes. 6. Cortisol 6 beta-hydroxylase was correlated with P450IIIA specific content. 7. The urinary level of 6 beta-hydroxycortisol correlated with liver microsomal cortisol 6 beta-hydroxylase and P450IIIA specific content. 8. We conclude that P450IIIA is predominantly responsible for cortisol 6 beta-hydroxylase activity in human liver microsomes and that urinary 6 beta-hydroxycortisol is a marker of the induction of this cytochrome P450.
机译:1.在利福平(每天口服600 mg,共4天)治疗前后的8至14例患者中,测定了6β-羟皮质醇,肝微粒体皮质醇6β-羟化酶的尿排泄以及几种形式的细胞色素P450的比含量。 。 2.利福平治疗可使尿中6β-羟基皮质醇的每日排泄量平均增加五倍。 3.皮质醇6β-羟化酶活性从器官供体(被视为“对照对象”)的15 +/- 6 pmol min-1 mg-1增加到利福平治疗患者的87 +/- 31 pmol min-1 mg-1 。 4.通过蛋白质印迹法测量的三种形式的人P450(P450IA,IIC和IIIA)(1),(2)中,只有P450IIIA被抗生素显着诱导。 5.只有抗P450IIIA的抗体在人肝微粒体中选择性抑制皮质醇6β-羟化酶。 6.皮质醇6β-羟化酶与P450IIIA的特定含量相关。 7.尿中的6β-羟基皮质醇水平与肝微粒体皮质醇6β-羟化酶和P450IIIA的特异性含量相关。 8.我们得出结论,P450IIIA主要负责人肝微粒体中皮质醇6β-羟化酶的活性,尿6β-羟基皮质醇是该细胞色素P450诱导的标志。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号